Visus Therapeutics is coming for AbbVie. After ceding a big head start to AbbVie’s recently approved Vuity, Visus has posted midphase data that advance its effort to come from behind in the new market for medicines to treat age-related long-sightedness.

AbbVie, working through its Allergan unit, is already on the market, and Eyenovia has phase 3 data on its rival candidate. Visus’ eye drop is further back, but the phase 2 data point to the potential for it to deliver a differentiated candidate. Notably, the midphase results provide early evidence in support of Visus’ framing of brimochol as a longer-lasting treatment.

Read the full article here.